000513.SZLivzon Pharmaceutical Group Inc.
The schedule
- Thu15Oct
Anticipated NMPA regulatory milestones for Livzon's complex injectables and microsphere pipeline, evaluating the potential to offset legacy generic margin compression from the $27.50 base.
- Fri30Oct
Q3 2026 Earnings Release, testing the narrative of a fundamental inflection point from $29.50 against easing year-over-year comparables.
- Wed20Jan
Expected National Volume-Based Procurement (VBP) bidding round, bringing mandatory price cuts to mature generic formulations and testing the $31.50 valuation.
- Fri26Mar
FY 2026 Earnings Release, detailing full-year free cash flow realization from $28.50 and the 2027 outlook amidst a challenging reimbursement landscape.
- Wed28Apr
Q1 2027 Earnings Release anchoring at $26.50, providing early evidence of sequential revenue stabilization and integration of the newest pricing dynamics.
Past
- Wed26Aug
Actual outcome: Bear · $27.35 at outcome
The stock closed below the bear floor of $27.50, indicating a bearish outcome. Despite the EPS matching estimates, the stock fell due to continued top-line erosion and weak guidance, which raised concerns about the company's ability to stabilize revenue growth.
Upcoming 1H 2026 financial results where the market will scrutinize top-line erosion against the $29.26 entry price, heavily focused on whether recent -9% revenue trends continue.